Balanced news tone
News Sentiment
ZNTL sentiment intelligence
Zentalis Pharmaceuticals Llc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+9.4% over one week, +30.1% over four weeks, trend active, and below fair value.
Zentalis Pharmaceuticals (ZNTL) Edges Higher, Stabilizing Near Support After Recent Volatility - Entry Point Alerts
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 21:39
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 20:05
- Source
- GlobeNewswire
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 20:05
- Source
- GlobeNewswire
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 12:00
- Source
- GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 21:30
- Source
- GlobeNewswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 14:27
- Source
- GlobeNewswire
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 20 Apr 2026 07:00
- Source
- Market source
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 19:15
- Source
- GlobeNewswire
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2026 07:00
- Source
- simplywall.st
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Apr 2026 07:00
- Source
- Market source
Is Zentalis (ZNTL) Using Azenosertib’s New Dose To Reframe Its Ovarian Cancer Strategy?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Apr 2026 07:00
- Source
- simplywall.st
What's Behind The Surge In Zentalis Stock?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- Sahm
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Zentalis Pharmaceuticals Stock (ZNTL) Opinions on Azenosertib Development Update | ZNTL Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jan 2026 08:00
- Source
- Quiver Quantitative
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jan 2026 08:00
- Source
- Investing.com
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jan 2026 08:00
- Source
- Market source
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jan 2026 08:00
- Source
- simplywall.st